JP2001519642A5 - - Google Patents

Download PDF

Info

Publication number
JP2001519642A5
JP2001519642A5 JP1997509463A JP50946397A JP2001519642A5 JP 2001519642 A5 JP2001519642 A5 JP 2001519642A5 JP 1997509463 A JP1997509463 A JP 1997509463A JP 50946397 A JP50946397 A JP 50946397A JP 2001519642 A5 JP2001519642 A5 JP 2001519642A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1997509463A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001519642A (ja
Filing date
Publication date
Priority claimed from US08/580,038 external-priority patent/US5807670A/en
Priority claimed from US08/639,857 external-priority patent/US5955318A/en
Application filed filed Critical
Publication of JP2001519642A publication Critical patent/JP2001519642A/ja
Publication of JP2001519642A5 publication Critical patent/JP2001519642A5/ja
Ceased legal-status Critical Current

Links

JP50946397A 1995-08-14 1996-08-14 肝炎gbvタンパクの翻訳の制御に有用な試薬および方法 Ceased JP2001519642A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US60/002,265 1995-08-11
US226595P 1995-08-14 1995-08-14
US08/580,038 US5807670A (en) 1995-08-14 1995-12-21 Detection of hepatitis GB virus genotypes
US08/580,038 1995-12-21
US08/639,857 1996-04-19
US08/639,857 US5955318A (en) 1995-08-14 1996-04-19 Reagents and methods useful for controlling the translation of hepatitis GBV proteins
PCT/US1996/013198 WO1997007224A1 (en) 1995-08-14 1996-08-14 Reagents and methods useful for controlling the translation of hepatitis gbv proteins

Publications (2)

Publication Number Publication Date
JP2001519642A JP2001519642A (ja) 2001-10-23
JP2001519642A5 true JP2001519642A5 (cg-RX-API-DMAC7.html) 2004-08-26

Family

ID=27357120

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50946397A Ceased JP2001519642A (ja) 1995-08-14 1996-08-14 肝炎gbvタンパクの翻訳の制御に有用な試薬および方法

Country Status (5)

Country Link
US (1) US5955318A (cg-RX-API-DMAC7.html)
EP (1) EP0845042A1 (cg-RX-API-DMAC7.html)
JP (1) JP2001519642A (cg-RX-API-DMAC7.html)
CA (1) CA2229143A1 (cg-RX-API-DMAC7.html)
WO (1) WO1997007224A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10002027A1 (de) * 2000-01-19 2001-07-26 Tenovis Gmbh & Co Kg Vorrichtung zur direkten Herstellung von Telekommunikationsverbindungen von einer TK-Anlage ins Mobilfunknetz
US6828105B2 (en) * 2001-10-16 2004-12-07 Avi Biopharma, Inc. Antisense antiviral agent and method for treating ssRNA viral infection
US20030224353A1 (en) * 2001-10-16 2003-12-04 Stein David A. Antisense antiviral agent and method for treating ssRNA viral infection
AU2002360417A1 (en) * 2001-11-26 2003-06-10 Duke University Genetically stable expression vector
WO2005013905A2 (en) * 2003-08-07 2005-02-17 Avi Biopharma, Inc. SENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING ssRNA VIRAL INFECTION
US20050222068A1 (en) * 2003-10-23 2005-10-06 Mourich Dan V Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells
US8129352B2 (en) 2004-09-16 2012-03-06 Avi Biopharma, Inc. Antisense antiviral compound and method for treating ssRNA viral infection
US8357664B2 (en) 2004-10-26 2013-01-22 Avi Biopharma, Inc. Antisense antiviral compound and method for treating influenza viral infection
US7524829B2 (en) 2004-11-01 2009-04-28 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
US20060240032A1 (en) * 2005-03-31 2006-10-26 Hinrichs David J Immunomodulating compositions and methods for use in the treatment of human autoimmune diseases
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
WO2007030691A2 (en) * 2005-09-08 2007-03-15 Avi Biopharma, Inc. Antisense antiviral compound and method for treating picornavirus infection
AU2006287530A1 (en) * 2005-09-08 2007-03-15 Sarepta Therapeutics, Inc. Antisense antiviral compound and method for treating picornavirus infection
US8501704B2 (en) * 2005-11-08 2013-08-06 Sarepta Therapeutics, Inc. Immunosuppression compound and treatment method
ES2390365T3 (es) * 2006-03-29 2012-11-12 Graphic Packaging International, Inc. Embalajes de transporte y método de montaje de embalajes de transporte
LT2735568T (lt) * 2006-05-10 2017-11-27 Sarepta Therapeutics, Inc. Oligonukleotido analogai, turintys katijonines jungtis tarp subvienetų
US8785407B2 (en) * 2006-05-10 2014-07-22 Sarepta Therapeutics, Inc. Antisense antiviral agent and method for treating ssRNA viral infection
US20100035248A1 (en) * 2007-06-15 2010-02-11 Rastislav Levicky Surface-based nucleic acid assays employing morpholinos
US8592386B2 (en) 2008-12-17 2013-11-26 Sarepta Therapeutics, Inc. Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
AU2010319314C1 (en) 2009-11-13 2016-09-01 Sarepta Therapeutics, Inc. Antisense antiviral compound and method for treating influenza viral infection
KR101981705B1 (ko) 2010-05-28 2019-05-24 사렙타 쎄러퓨틱스, 인코퍼레이티드 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
US8198429B2 (en) 2010-08-09 2012-06-12 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
WO2012031243A2 (en) 2010-09-03 2012-03-08 Avi Biopharma, Inc. dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
KR20140097398A (ko) 2011-11-18 2014-08-06 사렙타 쎄러퓨틱스, 인코퍼레이티드 기능적으로-변형된 올리고뉴클레오티드 및 이의 서브유니트
EP2927320B1 (en) * 2012-11-29 2019-09-04 Gifu University Rna interference agent, method for producing same, and use thereof
US11020417B2 (en) 2015-06-04 2021-06-01 Sarepta Therapeutics, Inc Methods and compounds for treatment of lymphocyte-related diseases and conditions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743535A (en) * 1984-11-07 1988-05-10 Miles Inc. Hybridization assay employing labeled probe and anti-hybrid
US4876187A (en) * 1985-12-05 1989-10-24 Meiogenics, Inc. Nucleic acid compositions with scissile linkage useful for detecting nucleic acid sequences
WO1989004669A1 (en) * 1987-11-18 1989-06-01 Chiron Corporation Nanbv diagnostics and vaccines
WO1990000597A1 (en) * 1988-07-06 1990-01-25 Genelabs Incorporated Post-transfusion, non-a, non-b hepatitis virus and antigens
JP2696116B2 (ja) * 1988-09-30 1998-01-14 財団法人阪大微生物病研究会 非a非b肝炎患者の血清と抗原抗体反応するペプチド、及び該ペプチドをコードするdna
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
DK0529493T3 (da) * 1991-08-27 1998-08-24 Hoffmann La Roche Fremgangsmåder og reagenser til hepatitis C-detektion
US5576302A (en) * 1991-10-15 1996-11-19 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity
WO1994018217A1 (en) * 1993-02-03 1994-08-18 Abbott Laboratories Non-a, non-b, non-c, non-d, non-e hepatitis reagents and methods for their use
DE69333914T2 (de) * 1992-09-28 2006-08-10 Chiron Corp., Emeryville Verfahren und zusammensetzungen zur kontrolle der übersetzung der hcv-proteine
AU673775B2 (en) * 1993-08-24 1996-11-21 Great Lakes Chemical Corporation Ophthalmic lenses
AU2549195A (en) * 1994-05-20 1995-12-18 Genelabs Technologies, Inc. Non-A/non-B/non-C/non-D/non-E hepatitis agents and molecular cloning thereof
ES2170152T3 (es) * 1994-05-20 2002-08-01 Genelabs Tech Inc Virus de la hepatitis g y clon molecular del mismo.
WO1995032292A2 (en) * 1994-05-20 1995-11-30 Genelabs Technologies, Inc. Detection of viral antigens coded by reverse-reading frames

Similar Documents

Publication Publication Date Title
JP2000500440A5 (cg-RX-API-DMAC7.html)
JP2000500445A5 (cg-RX-API-DMAC7.html)
JP2001526523A5 (cg-RX-API-DMAC7.html)
JP2000500228A5 (cg-RX-API-DMAC7.html)
JP2000500033A5 (cg-RX-API-DMAC7.html)
JP2000500327A5 (cg-RX-API-DMAC7.html)
JP2000500155A5 (cg-RX-API-DMAC7.html)
JP2000500406A5 (cg-RX-API-DMAC7.html)
JP2000500361A5 (cg-RX-API-DMAC7.html)
JP2000500115A5 (cg-RX-API-DMAC7.html)
JP2000500322A5 (cg-RX-API-DMAC7.html)
JP2000500342A5 (cg-RX-API-DMAC7.html)
JP2000500192A5 (cg-RX-API-DMAC7.html)
JP2000500112A5 (cg-RX-API-DMAC7.html)
JP2000500166A5 (cg-RX-API-DMAC7.html)
JP2000500051A5 (cg-RX-API-DMAC7.html)
JP2000500407A5 (cg-RX-API-DMAC7.html)
JP2000500397A5 (cg-RX-API-DMAC7.html)
JP2000500125A5 (cg-RX-API-DMAC7.html)
JP2001517922A5 (cg-RX-API-DMAC7.html)
JP2000500044A5 (cg-RX-API-DMAC7.html)
JP2000500257A5 (cg-RX-API-DMAC7.html)
JP2000500090A5 (cg-RX-API-DMAC7.html)
JPH11515033A5 (cg-RX-API-DMAC7.html)
JPH10509740A5 (cg-RX-API-DMAC7.html)